In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: Relative lack of immunogenicity of B16 melanoma cells

Ashley, Michael P.; Kotlarski, Ieva

doi:10.1016/0008-8749(86)90194-2

Cited by 10 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(19; 20). Preimmunisation with live B16 at a remote site also led to the killing of labelled B16 cells injected i.p., although on a cell-for-cell basis 100 x more B16 cells than H-2'' bearing PC were required to give a comparable level of immunity (20). This result, together with that of Heath and Boyle (19), showing that B16 cells can prime in vivo for an in vitro secondary cytotoxic response, confirms that these cells are capable of inducing, albeit inefficiently, an anti-H-2'' response.…”

Section: Tumour Immunogenicity In Allogeneic Systemssupporting

confidence: 57%

“…Using an assay of the lysis of '^^I-labelled tumour cells in vivo, Ashley and Kotlarski (20) showed that B16, unlike the highly immunogenic H-2'' lymphoma EL4, failed to elicit an early cytotoxic response in BALB/c mice. Preimmunisation with irradiated B16 at relatively high doses (3-5x10^) 7 to 10 days prior to challenge was protective against B16 i.p.…”

Section: Tumour Immunogenicity In Allogeneic Systemsmentioning

confidence: 99%

See 1 more Smart Citation

The immunogenicity of tumour cells

Ashman

1987

Immunol Cell Biol

View full text Add to dashboard Cite

Summary Immunological mechanisms are demonstrably of central importance in preventing the development of certain virus‐associated cancers in animals and man; however, they do not appear to fulfil this role in the majority of ‘spontaneous’ tumours. This does not, however, necessarily indicate that spontaneous tumours lack potential target antigens for immunologically mediated destruction. Work in the field of transplantation immunology has clearly shown that certain cell types fail to elicit rejection reactions despite their possession of alloantigens. Similarly, some tumour cell types are poorly immunogenic to the point that they can grow in and kill animals despite a major histocompatability barrier. These tumours are, however, susceptible to destruction in vivo in appropriately allo‐sensitized animals. Thus, some tumours may be able to grow in autologous or syngeneic hosts because of their poor immunogenicity, despite the fact that they express potential (tumour‐associated) rejection antigens. It may be possible to manipulate this situation for therapeutic purposes.

show abstract

Section: Tumour Immunogenicity In Allogeneic Systemssupporting

confidence: 57%

Section: Tumour Immunogenicity In Allogeneic Systemsmentioning

confidence: 99%

The immunogenicity of tumour cells

Ashman

1987

Immunol Cell Biol

View full text Add to dashboard Cite

show abstract

“…Cells used for experiments had been subcultured in vitro at least 7 times and no more than 15 times. The cells were grown as adherent monolayers and harvested as described previously (4), except ihat the cells were removed Irom the flasks wiih EUTA (O02'''o w/v) but without trypsin.…”

Section: Tumoursmentioning

confidence: 99%

“…However, it expresses sufficient MHC antigens to be lysed in vivo (4) and in vitro (5), provided that the response is either aided by lymphokine or induced by other cells carrying H-2*' antigens.…”

Section: Introductionmentioning

confidence: 99%

“…It has been known for a long time that antigenic tumours are able to survive the host's immune system by a variety of means. We and others (2)(3)(4)(5) have suggested that one of these means might be illustrated by tumours such as the B16 melanoma of C57BL/6 mice which appears to be a very poor stimulator of responses to its own antigens, even to its major histocompatibility complex antigens (3)(4)(5)(6). Thus, some tumours may fail to immunize, not Abbreviations used in this paper CTL, cytolyiic T lymphocyte; f.p., footpad; i.p., intraperitoneal(ly); MHC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo H‐2K and H‐2D antigen expression In two allogeneic mouse tumours of low immunogenicity

Ashley

Kotlarski

1987

Immunol Cell Biol

Self Cite

View full text Add to dashboard Cite

Summary The B16 melanoma of C57BL/6 mice immunizes very poorly, even against its own major histocompatibility complex (MHC) antigens. B16 cells expressed both H‐2K and H‐2D antigens in vitro as judged by binding of monoclonal antibodies to these antigens in indirect immunofluorescence staining. The in vivo MHC antigen expression of B16 was examined and compared with that of a second C57BL/6 tumour, the Lewis lung carcinoma (3LL). whose defective immunogenicity has been attributed to a selective deficiency‐ in H‐2K antigen expression. We found that 125I‐labeiled cells of both tumours expressed sufficient allo‐antigen in vivo to be lysed in BALB/c mice which had been pre‐immunized with C57BL/6 lymphoid cells. 125I‐B16 cells were also lysed in MHC‐recombinant mice which had been immunized against either H‐2Kb or H‐2Db, indicating that B16 cells express both of these MHC antigens in vivo. This contrasted with our findings with 125I‐3LL cells which were destroyed in mice immunized against H‐2Db but not in those immunized against H‐2Kb. Thus, B16 illustrates a different deficiency in tumour cell immunogenicity which appears not to be attributable to an absence of either of the class 1 MHC antigens.

show abstract